高脂血症的研究进展
Research Progress on Hyperlipidemia
DOI: 10.12677/ACM.2024.141235, PDF,   
作者: 李成消, 冷建春*：成都中医药大学附属医院全科医学科，四川 成都
关键词: 高脂血症；降脂药物；饮食管理；运动管理；Hyperlipidemia； Lipid-Lowering Drugs； Diet Management； Exercise Management
摘要: 本文就高脂血症的分类、药物治疗的研究进展以及饮食和运动管理方面的重要性进行了综述。首先，高脂血症可分为原发性和继发性两种类型，根据不同的致病因素和遗传背景进行分类。其次，药物治疗方面的研究已取得显著进展，包括降胆固醇药物和降甘油三酯药物等。他汀类药物是降胆固醇治疗的基石，而其他药物如胆固醇吸收抑制剂和PCSK9抑制剂也显示了良好的疗效。此外，降甘油三酯药物如贝特类药物、烟酸类药物和高纯度鱼油制剂在降低甘油三酯水平方面发挥重要作用。最后，饮食和运动管理在高脂血症患者中起着关键作用。通过合理的饮食结构和适度的运动，可以进一步改善血脂水平并降低心血管疾病的风险。
Abstract: This article provides a comprehensive review on the classification of hyperlipidemia, research pro-gress in drug therapy, and the importance of diet and exercise management. Firstly, hyperlipidemia can be classified into primary and secondary types based on different etiological factors and genetic backgrounds. Secondly, significant progress has been made in drug therapy, including cholester-ol-lowering drugs and triglyceride-lowering drugs. Statins are the cornerstone of cholester-ol-lowering treatment, while other drugs such as cholesterol absorption inhibitors and PCSK9 in-hibitors have also shown good efficacy. In addition, triglyceride-lowering drugs such as fibrates, nia-cin, and high-purity fish oil preparations play an important role in reducing triglyceride levels. Lastly, diet and exercise management play a crucial role in patients with hyperlipidemia. By adopt-ing a balanced diet and engaging in moderate exercise, blood lipid levels can be further improved and the risk of cardiovascular diseases can be reduced.
文章引用：李成消, 冷建春. 高脂血症的研究进展[J]. 临床医学进展, 2024, 14(1): 1635-1646. https://doi.org/10.12677/ACM.2024.141235

参考文献

[1] Beaumont, J.L., Carlson, L.A., Cooper, G.R., Fejfar, Z., Fredrickson, D.S. and Strasser, T. (1970) Classification of Hy-perlipidaemias and Hyperlipoproteinaemias. Bulletin of the World Health Organization, 43, 891-915.
[2] 中国血脂管理指南修订联合专家委员会. 中国血脂管理指南(2023年) [J]. 中华心血管病杂志, 2023, 51(3): 221-255. [Google Scholar] [CrossRef] [PubMed]
[3] Beheshti, S.O., Madsen, C.M., Varbo, A. and Nordestgaard, B.G. (2020) Worldwide Prevalence of Familial Hypercholesterolemia: Meta-Analyses of 11 Million Sub-jects. Journal of the American College of Cardiology, 75, 2553-2566. [Google Scholar] [CrossRef] [PubMed]
[4] Enito-Vicente, A., Uribe, K.B., Jebari, S., Galicia-Garcia, U., Osto-laza, H. and Martin, C. (2018) Familial Hypercholesterolemia: The Most Frequent Cholesterol Metabolism Disorder Caused Disease. International Journal of Molecular Sciences, 19, Article No. 3426. [Google Scholar] [CrossRef] [PubMed]
[5] Singh, S. and Bittner, V. (2015) Familial Hypercholesterole-mia—Epidemiology, Diagnosis, and Screening. Current Atherosclerosis Reports, 17, Article No. 482. [Google Scholar] [CrossRef] [PubMed]
[6] Nordestgaard, B.G., Chapman, M.J., Humphries, S.E., Ginsberg, H.N., Masana, L., Descamps, O.S., et al. (2013) Familial Hypercholesterolaemia Is Underdiagnosed and Undertreated in the General Population: Guidance for Clinicians to Prevent Coronary Heart Disease: Consensus Statement of the Euro-pean Atherosclerosis Society. European Heart Journal, 34, 3478-3490. [Google Scholar] [CrossRef] [PubMed]
[7] Hegele, R.A., BorÉN, J., Ginsberg, H.N., Arca, M., Averna, M., Binder, C.J., et al. (2020) Rare Dyslipidaemias, from Phenotype to Genotype to Management: A European Atherosclero-sis Society Task Force Consensus Statement. The Lancet Diabetes & Endocrinology, 8, 50-67. [Google Scholar] [CrossRef] 
[8] Kayikcioglu, M., Kısmalı, E., Can, L. and Payzin, S. (2014) Long-Term Follow-Up in Patients with Homozygous Familial Hypercholesterolemia, 13-Year Experience of a University Hospital Lipid Clinic. Türk Kardiyoloji Derneği Arşivi, 42, 599-611. [Google Scholar] [CrossRef] [PubMed]
[9] Defesche, J.C., Gidding, S.S., Harada-Shiba, M., Hegele, R.A., Santos, R.D. and Wierzbicki, A.S. (2017) Familial Hypercholesterolaemia. Nature Reviews Disease Primers, 7, Article No. 17093. [Google Scholar] [CrossRef] [PubMed]
[10] Brænne, I., Kleinecke, M., Reiz, B., Graf, E., Strom, T., Wieland, T., et al. (2016) Systematic Analysis of Variants Related to Familial Hypercholesterolemia in Families with Premature Myocardial Infarction. European Journal of Human Genetics, 24, 191-197. [Google Scholar] [CrossRef] [PubMed]
[11] Kayikcioglu, M., Tokgozoglu, L., Dogan, V., Ceyhan, C., Tuncez, A., Kutlu, M., et al. (2018) What Have We Learned from Turkish Familial Hypercholesterolemia Registries (A-HIT1 and A-HIT2)? Atherosclerosis, 277, 341-346. [Google Scholar] [CrossRef] [PubMed]
[12] Trinder, M., Vikulova, D., Pimstone, S., Mancini, G.B.J. and Brunham, L.R. (2022) Polygenic Architecture and Cardiovascular Risk of Familial Combined Hyperlipidemia. Ath-erosclerosis, 340, 35-43. [Google Scholar] [CrossRef] [PubMed]
[13] Nawawi, H.M., Chua, Y.A. and Watts, G.F. (2020) The Brave New World of Genetic Testing in the Management of the Dyslipidaemias. Current Opinion in Cardiology, 35, 226-233. [Google Scholar] [CrossRef] 
[14] Taghizadeh, E., Farahani, N., Mardani, R., et al. (2022) Genetics of Familial Combined Hyperlipidemia (FCHL) Disorder: An Update. Biochemical Genetics, 60, 453-481. [Google Scholar] [CrossRef] [PubMed]
[15] Gill, P.K. and Hegele, R.A. (2022) Familial Combined Hyper-lipidemia Is a Polygenic Trait. Current Opinion in Lipidology, 33, 126-132. [Google Scholar] [CrossRef] 
[16] Taghizadeh, E., Esfehani, R.J., Sahebkar, A., Parizadeh, S.M., Rostami, D., Mirinezhad, M., et al. (2019) Familial Combined Hyperlipidemia: An Overview of the Underlying Molecular Mechanisms and Therapeutic Strategies. IUBMB Life, 71, 1221-1229. [Google Scholar] [CrossRef] [PubMed]
[17] Hopkins, P.N., Wu, L.L., Hunt, S.C. and Brinton, E.A. (2005) Plasma Tri-glycerides and Type III Hyperlipidemia Are Independently Associated with Premature Familial Coronary Artery Disease. Journal of the American College of Cardiology, 45, 1003-1012. [Google Scholar] [CrossRef] [PubMed]
[18] Riccardi, G., Vaccaro, O., Costabile, G. and Rivellese, A.A. (2016) How Well Can We Control Dyslipidemias through Lifestyle Modifications? Current Cardiology Reports, 18, Article No. 66. [Google Scholar] [CrossRef] [PubMed]
[19] Falko, J.M. (2018) Familial Chylomicronemia Syndrome: A Clinical Guide for Endocrinologists. Endocrine Practice, 24, 756-763. [Google Scholar] [CrossRef] 
[20] Chou, R., Dana, T., Blazina, I., Daeges, M. and Jeanne, T.L. (2016) Statins for Prevention of Cardiovascular Disease in Adults: Evidence Report and Systematic Review for the US Preven-tive Services Task Force. JAMA, 316, 2008-2024. [Google Scholar] [CrossRef] [PubMed]
[21] Mills, E.J., O’Regan, C., Eyawo, O., Wu, P., Mills, F., Berwanger, O. and Briel, M. (2011) Intensive Statin Therapy Compared with Moderate Dosing for Prevention of Cardiovascular Events: A Meta-Analysis of > 40 000 Patients. European Heart Journal, 32, 1409-1415. [Google Scholar] [CrossRef] [PubMed]
[22] Cannon, C.P., Steinberg, B.A., Murphy, S.A., Mega, J.L. and Braunwald, E. (2006) Meta-Analysis of Cardiovascular Outcomes Trials Comparing Intensive versus Moderate Statin Therapy. Journal of the American College of Cardiology, 48, 438-445. [Google Scholar] [CrossRef] [PubMed]
[23] Rodriguez, F., Maron, D.J., Knowles, J.W., Virani, S.S., Lin, S. and Heidenreich, P.A. (2017) Association between Intensity of Statin Therapy and Mortality in Patients with Atheroscle-rotic Cardiovascular Disease. JAMA Cardiology, 2, 47-54. [Google Scholar] [CrossRef] [PubMed]
[24] Silva, M., Matthews, M.L., Jarvis, C., Nolan, N.M., Belliveau, P., Malloy, M. and Gandhi, P. (2007) Meta-Analysis of Drug-Induced Adverse Events Associated with Intensive-Dose Statin Therapy. Clinical Therapeutics, 29, 253-260. [Google Scholar] [CrossRef] [PubMed]
[25] Kim, B.K., Hong, S.J., Lee, Y.J., Hong, S.J., Yun, K.H., Hong, B.K., et al. (2022) Long-Term Efficacy and Safety of Moderate-Intensity Statin with Ezetimibe Combination Therapy versus High-Intensity Statin Monotherapy in Patients with Atherosclerotic Cardiovascular Disease (RACING): A Ran-domised, Open-Label, Non-Inferiority Trial. The Lancet, 400, 380-390. [Google Scholar] [CrossRef] 
[26] Zhang, X., Xing, L., Jia, X., Pang, X., Xiang, Q., Zhao, X., et al. (2020) Comparative Lipid-Lowering/Increasing Efficacy of 7 Statins in Patients with Dyslipidemia, Cardiovascular Diseases, or Diabetes Mellitus: Systematic Review and Network Meta-Analyses of 50 Randomized Controlled Trials. Cardiovascular Therapeutics, 2020, Article ID: 3987065. [Google Scholar] [CrossRef] [PubMed]
[27] Awad, K. and Banach, M. (2018) The Optimal Time of Day for Statin Administration: A Review of Current Evidence. Current Opinion in Lipidology, 29, 340-345. [Google Scholar] [CrossRef] 
[28] Awad, K., Serban, M.C., Penson, P., Mikhailidis, D.P., Toth, P.P., Jones, S.R., Rizzo, M., et al. (2017) Effects of Morning vs Evening Statin Administration on Lipid Profile: A Systematic Review and Meta-Analysis. Journal of Clinical Lipidology, 11, 972-985.E9. [Google Scholar] [CrossRef] [PubMed]
[29] 高海洋, 汪芳. 他汀类药物导致肝损伤的诊断和监测[J]. 心血管病学进展, 2017, 38(3): 271-276. [Google Scholar] [CrossRef] 
[30] Björnsson, E., Jacobsen, E.I. and Kalaitzakis, E. (2012) Hepatotoxicity Associated with Statins: Reports of Idiosyncratic Liver Injury Post-Marketing. Journal of Hepa-tology, 56, 374-380. [Google Scholar] [CrossRef] [PubMed]
[31] Stroes, E.S., Thompson, P.D., Corsini, A., Vladutiu, G.D., Raal, F.J., Ray, K.K., et al. (2015) Statin-Associated Muscle Symptoms: Impact on Statin Thera-py-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. European Heart Journal, 36, 1012-1022. [Google Scholar] [CrossRef] [PubMed]
[32] 陈宇, 李银洛, 唐才林, 等. 瑞舒伐他汀引起新发糖尿病的研究进展[J]. 中国糖尿病杂志, 2022, 30(9): 712-714.
[33] Mach, F., Ray, K.K., Wiklund, O., Corsini, A., Catapano, A.L., Bruckert, E., et al. (2018) Adverse Effects of Statin Therapy: Perception vs. the Evi-dence—Focus on Glucose Homeostasis, Cognitive, Renal and Hepatic Function, Haemorrhagic Stroke and Cataract. Eu-ropean Heart Journal, 39, 2526-2539. [Google Scholar] [CrossRef] [PubMed]
[34] Capps, N. (2006) Total and Low-Density Lipoprotein Cholesterol Responses to Ezetimibe in Clinical Practice. International Journal of Clinical Prac-tice, 60, 867-869. [Google Scholar] [CrossRef] [PubMed]
[35] 王依繁, 张翼, 林阳. 他汀类药物联合依折麦布用于冠心病患者治疗的有效性和安全性评价[J]. 中国医院药学杂志, 2022, 42(5): 538-543. [Google Scholar] [CrossRef] 
[36] 中等强度他汀+依折麦布, 优于单用高强度他汀[J]. 中国循证心血管医学杂志, 2023, 15(5): 634.
[37] Phan, B.A., Dayspring, T.D. and Toth, P.P. (2012) Ezetimibe Therapy: Mechanism of Action and Clinical Update. Vascular Health and Risk Management, 8, 415-427. [Google Scholar] [CrossRef] 
[38] Chen, W., Ruan, Z., Chen, J., Yang, D., Shao, R., Lou, H. and Jiang, B. (2022) Population Pharmacokinetics and Enterohepatic Recirculation of Hyzetimibe and Its Main Metabolite in Chi-nese Healthy Subjects. British Journal of Clinical Pharmacology, 88, 3153-3161. [Google Scholar] [CrossRef] [PubMed]
[39] Ballantyne, C.M., Banka, P., Mendez, G., Garcia, R., Rosenstock, J., Rodgers, A., Mendizabal, G., Mitchel, Y. and Catapano, A.L. (2023) Phase 2b Randomized Trial of the Oral PCSK9 In-hibitor MK-0616. Journal of the American College of Cardiology, 81, 1553-1564. [Google Scholar] [CrossRef] [PubMed]
[40] Guedeney, P., Giustino, G., Sorrentino, S., Claessen, B.E., Camaj, A., Kalkman, D.N., et al. (2019) Efficacy and Safety of Alirocumab and Evolocumab: A Systematic Review and Me-ta-Analysis of Randomized Controlled Trials. European Heart Journal, 43, e17-e25. [Google Scholar] [CrossRef] [PubMed]
[41] Pokhrel, B., Yuet, W.C. and Levine, S.N. (2023) PCSK9 Inhibitors. StatPearls Publishing, Treasure Island.
[42] Pirillo, A., Catapano, A.L. and Norata, G.D. (2021) Monoclonal Antibodies in the Management of Familial Hypercholesterolemia: Focus on PCSK9 and ANGPTL3 Inhibitors. Current Atheroscle-rosis Reports, 23, Article No. 79. [Google Scholar] [CrossRef] [PubMed]
[43] Ge, X., Zhu, T., Zeng, H., Yu, X., Li, J., Xie, S., et al. (2021) A Systematic Review and Meta-Analysis of Therapeutic Efficacy and Safety of Alirocumab and Evolocumab on Familial Hypercholesterolemia. BioMed Research International, 2021, Article ID: 8032978. [Google Scholar] [CrossRef] [PubMed]
[44] Gallego-Colon, E., Daum, A. and Yosefy, C. (2020) Statins and PCSK9 Inhibitors: A New Lipid-Lowering Therapy. European Journal of Pharmacology, 878, Article ID: 173114. [Google Scholar] [CrossRef] [PubMed]
[45] Ray, K.K., Wright, R.S., Kallend, D., Koenig, W., Leiter, L.A., Raal, F.J., et al. (2020) Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. The New England Journal of Medicine, 382, 1507-1519. [Google Scholar] [CrossRef] 
[46] Warden, B.A. and Duell, P.B. (2021) Inclisiran: A Novel Agent for Lowering Apolipoprotein B-Containing Lipoproteins. Journal of Cardiovascular Pharmacology, 78, E157-E174. [Google Scholar] [CrossRef] 
[47] Yamashita, S., Masuda, D. and Matsuzawa, Y. (2020) Pem-afibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases. Current Atherosclerosis Reports, 22, Article No. 5. [Google Scholar] [CrossRef] [PubMed]
[48] Julius, U. and Fischer, S. (2013) Nicotinic Acid as a Li-pid-Modifying Drug—A Review. Atherosclerosis Supplements, 14, 7-13. [Google Scholar] [CrossRef] [PubMed]
[49] HPS2-THRIVE Collaborative Group, Landray, M.J., Haynes, R., Hopewell, J.C., Parish, S., Aung, T., Tomson, J., et al. (2014) Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients. The New England Journal of Medicine, 371, 203-212. [Google Scholar] [CrossRef] 
[50] AIM-HIGH Investigators, Boden, W.E., Probstfield, J.L., Anderson, T., Chaitman, B.R., Desvignes-Nickens, P., Koprowicz, K., McBride, R., Teo, K. and Weintraub, W. (2011) Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy. The New England Journal of Medicine, 365, 2255-2267. [Google Scholar] [CrossRef] 
[51] HPS2-THRIVE Collaborative Group; Landray, M.J., Haynes, R., Hopewell, J.C., Parish, S., Aung, T., Tomson, J., Wallendszus, K., Craig, M., Jiang, L., Collins, R. and Armitage, J. (2014) Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients. The New England Journal of Medi-cine, 371, 203-212.
[52] Laufs, U., Banach, M., Mancini, G.B.J., Gaudet, D., Bloedon, L.T., Sterling, L.R., Kelly, S. and Stroes, E.S.G. (2019) Efficacy and Safety of Bempedoic Acid in Patients with Hypercholesterolemia and Statin In-tolerance. Journal of the American Heart Association, 8, E011662. [Google Scholar] [CrossRef] 
[53] Nissen, S.E., Lincoff, A.M., Brennan, D., Ray, K.K., Mason, D., Kastelein, J.J.P., et al. (2023) Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. The New Eng-land Journal of Medicine, 388, 1353-1364. [Google Scholar] [CrossRef] 
[54] Ballantyne, C.M., Laufs, U., Ray, K.K., Leiter, L.A., Bays, H.E., Goldberg, A.C., et al. (2020) Bempedoic Acid plus Ezetimibe Fixed-Dose Combination in Patients with Hypercholester-olemia and High CVD Risk Treated with Maximally Tolerated Statin Therapy. European Journal of Preventive Cardiol-ogy, 27, 593-603. [Google Scholar] [CrossRef] 
[55] Markham, A. (2021) Evinacumab: First Approval. Drugs, 81, 1101-1105. [Google Scholar] [CrossRef] [PubMed]
[56] Feingold, K.R. (2021) Triglyceride Lowering Drugs. In: Feingold, K.R., Anawalt, B., Blackman, M.R., Boyce, A., Chrousos, G., Corpas, E., De Herder, W.W., Dhatariya, K., et al., Eds., Endotext, MDText.Com, Inc., South Dartmouth, 2000.
[57] Watanabe, Y. and Tatsuno, I. (2020) Prevention of Cardiovascular Events with Omega-3 Polyunsaturated Fatty Acids and the Mechanism Involved. Journal of Athero-sclerosis and Thrombosis, 27, 183-198. [Google Scholar] [CrossRef] [PubMed]
[58] Kirkpatrick, C.F., Sikand, G., Petersen, K.S., Anderson, C.A.M., Aspry, K.E., Bolick, J.P., Kris-Etherton, P.M. and Maki, K.C. (2023) Nutrition Interventions for Adults with Dyslipidemia: A Clinical Perspective from the National Lipid Association. Journal of Clinical Lipidology, 17, 428-451. [Google Scholar] [CrossRef] [PubMed]
[59] Nie, Y. and Luo, F. (2021) Dietary Fiber: An Opportunity for a Global Control of Hyperlipidemia. Oxidative Medicine and Cellular Longevity, 2021, Article ID: 5542342. [Google Scholar] [CrossRef] [PubMed]
[60] Makhmudova, U., Schulze, P.C., Lütjohann, D. and Weingärtner, O. (2021) Phytosterols and Cardiovascular Disease. Current Atherosclerosis Reports, 23, Article No. 68. [Google Scholar] [CrossRef] [PubMed]
[61] Zhao, S., Zhong, J., Sun, C. and Zhang, J. (2021) Effects of Aerobic Exercise on TC, HDL-C, LDL-C and TG in Patients with Hyperlipidemia: A Protocol of Systematic Review and Meta-Analysis. Medicine (Baltimore), 100, E25103. [Google Scholar] [CrossRef] 
[62] De Matos, D.G., De Almeida-Neto, P.F., Moreira, O.C., De Souza, R.F., Tinoco Cabral, B.G.A., Chilibeck, P. and Aidar, F.J. (2021) Two Weekly Sessions of High-Intensity Inter-val Training Improve Metabolic Syndrome and Hypertriglyceridemic Waist Phenotype in Older Adults: A Randomized Controlled Trial. Metabolic Syndrome and Related Disorders, 19, 332-339. [Google Scholar] [CrossRef] [PubMed]

为你推荐